Umbilical cord blood transplantation.
OBJECTIVE
Familiar and unrelated umbilical cord blood is an appealing alternative source of hematopoietic stem cells patients undergoing transplantation for a wide variety of diseases. In the unrelated donor transplant setting, shorter time to transplant, which is particularly relevant to patients requiring urgent transplantation, and tolerance of 1-2 human leukocyte antigen mismatch, which increases the chance of finding a suitable donor, are evident advantages over bone marrow transplantation. The speed of engraftment is slower after cord blood transplantation but it is counterbalanced by a lower incidence of severe graft-versus-host disease. Cell dose and human leukocyte antigen are major factors influencing outcome after umbilical cord blood transplantation.


RESULTS
Unrelated donor cord blood transplantation is considered an acceptable option to bone marrow for pediatric transplantation, and recent data in adults point the same way.


CONCLUSIONS
This review describes the recent clinical results of cord blood transplantation and discusses developing research strategies aimed at optimizing this kind of transplantation.
Rocha
Vanderson
V
Eurocord Office, Bone Marrow Transplant, Hematology Department, Hôpital Saint Louis, Paris, France. vanderson.rocha@sls.ap-hop-paris.fr
Sanz
Guillermo
G
Gluckman
Eliane
E
D016026:Bone Marrow Transplantation; D036101:Cord Blood Stem Cell Transplantation; D005260:Female; D006085:Graft Survival; D006086:Graft vs Host Disease; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D011247:Pregnancy; D023001:Transplantation Tolerance